A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.  This study will evaluate the effects of the use of a program to reduce prescribing of a group of commonly prescribed medications called anticholingerics that may adversely effect cognitive functioning in older adults. THIS STUDY IS ENROLLING BY INVITATION ONLY - ResNet data managers will identify physicians from the medical records of Community Health Network, and these participating physicians' patients will be approached for recruitment.' They may be contacted by phone or during clinic visits upon referral from physician.  Physicians agreeing to participate in the study will be randomized to intervention or usual care in random blocks of two or four and stratified by clinic site. Physician randomization status will determine participants’ study groups. Physicians randomized to usual care will not have access to the intervention. Physicians are not the subjects of the study. The subjects are the patients of the physicians. Physicians will not be aware of how or when their patients are being recruited or for what studies they will be offered.

This sub-study consists of a single treatment group of men that require a PET scan to guide their radical prostatectomy, every subject will receive an MRI and the PSMA (prostate specific membrane antigen) PET scan prior to their surgery to determine if the PSMA PET scan is helpful in detecting prostate cancer at the edge of the prostate and guiding surgical treatment. The main outcome of this study is to review the sensitivity/specificity for extra-prostatic extension at the nerve bundles. A secondary goal for this cohort is to measure the proportion of patients whose treatment plan would be changed by PSMA-PET measured through changes in resection plans that affect one of 4 critical regions for quality of life.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to assess the efficacy and safety of RO7790121 (formerly PF-06480605 and RVT-3101) in patients with moderately to severely active Crohn's disease (CD). RO7790121 is a fully human neutralizing immunoglobulin G monoclonal antibody (mAb) against tumor necrosis factor-like ligand 1A (TL1A). TL1A plays a central role in the regulation of gut mucosal immunity and participates in immunological and fibrosis pathways involved in inflammatory bowel disease pathogenesis by binding its receptor, death receptor 3.THIS STUDY IS ENROLLING BY INVITATION ONLY

The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of high-energy lower extremity fractures (HELEF) will decrease the patients' risk of surgical site infections (SSI), particularly those caused by Staphylococcus aureus. THIS STUDY IS ENROLLING BY INVITATION ONLY

Low dose radiation in the treatment of benign diseases, including musculoskeletal disorders such as arthritis, is a standard clinical practice commonly utilized in some practices in the United States and even more commonly utilized in countries in Europe. This study will evaluate patients' pain and quality of life responses to this standard treatment through the use of surveys before and after their treatment for arthritis in our facilities.THIS STUDY IS ENROLLING BY INVITATION ONLY - Surveys and chart review will be performed within hospital clinics at IU Health for patients receiving LDRT for osteoarthritis. Some patients may be referred by other physicians or hear from word of mouth about this study. Patients will be seen in clinic during routine consultation appointments, and the study will be explained to them then. We will also email potential referring providers to let them know about the study using the provided email template.After consenting to the study, they will fill out pain score and quality of life surveys before and after undergoing the standard treatment with LDRT.

This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Over the past 10 years, new medication options have been approved for patients with IBD who did not respond to anti-TNF treatments. However, data is still limited for how these new medications work.   This study may provide researchers with valuable information about the continued use of these medications. The purpose of this study is to compare the effectiveness and safety of these newer IBD medications. COMPARE is a multi-center, observational cohort study that includes both prospective and retrospective components and two patient population cohorts-Crohn's disease (CD) and ulcerative colitis (UC). THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants with CD and 550 with UC or IBD-U whose disease is refractory to anti-TNF therapy will be identified and contact by the research team about study participation.